Medacta Group Sa Stock Net Income
| MEDGF Stock | USD 83.91 0.00 0.00% |
Fundamental analysis of Medacta Group allows traders to better anticipate movements in Medacta Group's stock price by examining its financial health and performance throughout various phases of its business cycle.
Medacta |
Medacta Group SA Company Net Income Analysis
Medacta Group's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Medacta Group Net Income | 51.52 M |
Most of Medacta Group's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medacta Group SA is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Medacta Group SA reported net income of 51.52 M. This is 84.9% lower than that of the Healthcare sector and 78.36% lower than that of the Medical Devices industry. The net income for all United States stocks is 90.98% higher than that of the company.
Medacta Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medacta Group's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Medacta Group could also be used in its relative valuation, which is a method of valuing Medacta Group by comparing valuation metrics of similar companies.Medacta Group is currently under evaluation in net income category among its peers.
Medacta Fundamentals
| Return On Equity | 0.21 | |||
| Return On Asset | 0.0752 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 2.11 B | |||
| Shares Outstanding | 19.98 M | |||
| Shares Owned By Insiders | 69.53 % | |||
| Shares Owned By Institutions | 17.99 % | |||
| Price To Earning | 37.53 X | |||
| Price To Book | 6.32 X | |||
| Price To Sales | 5.60 X | |||
| Revenue | 363.13 M | |||
| Gross Profit | 261.25 M | |||
| EBITDA | 99.33 M | |||
| Net Income | 51.52 M | |||
| Cash And Equivalents | 22.24 M | |||
| Cash Per Share | 1.11 X | |||
| Total Debt | 47.7 M | |||
| Debt To Equity | 0.67 % | |||
| Current Ratio | 2.76 X | |||
| Book Value Per Share | 12.62 X | |||
| Cash Flow From Operations | 54.06 M | |||
| Earnings Per Share | 2.52 X | |||
| Number Of Employees | 1.42 K | |||
| Beta | 1.12 | |||
| Market Capitalization | 2.17 B | |||
| Total Asset | 489.27 M | |||
| Z Score | 27.0 | |||
| Annual Yield | 0.01 % | |||
| Net Asset | 489.27 M | |||
| Last Dividend Paid | 0.54 |
About Medacta Group Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medacta Group SA's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medacta Group using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medacta Group SA based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Medacta Pink Sheet
Medacta Group financial ratios help investors to determine whether Medacta Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medacta with respect to the benefits of owning Medacta Group security.